A randomised study to optimise clinical outcomes in patients with FLT3 mutant AML

  • Wei, Andrew (Primary Chief Investigator (PCI))
  • Bradstock, Kenneth (Chief Investigator (CI))
  • Levis, Mark (Chief Investigator (CI))
  • Murray, Michael (Chief Investigator (CI))
  • Roberts, Andrew W. (Chief Investigator (CI))

Project: Research

Project Details

StatusFinished
Effective start/end date1/01/1331/12/17

Funding

  • National Health and Medical Research Council (NHMRC) (Australia): AUD1,111,891.00